Who Is a Candidate for Deep Brain Stimulation in Parkinson Disease? What the Evaluation Tests

The pill timer goes off again at the kitchen table. For the first years after diagnosis, one tablet in the morning carried him smoothly through to lunch. Now there is a stretch, sometime mid-morning, when his right hand stiffens and his feet feel glued to the floor, followed an hour later by the restless, writhing movements his neurologist calls dyskinesia. His daughter has read about a surgery that puts thin wires in the brain. He wants to know whether it is for people like him, and, just as much, whether it is for people like him yet.

That question, who is a candidate for DBS in Parkinson’s, is the one movement disorder clinics spend the most time answering, and the honest reply is rarely a simple yes or no. It is a structured evaluation with several distinct tests, each designed to answer a different question.

This article walks through what those tests look for, why they matter, and what people commonly misunderstand about the whole process.

What deep brain stimulation actually does in the brain

Deep brain stimulation is a surgical treatment in which one or two thin electrodes are placed in precise regions deep inside the brain and connected by a wire under the skin to a small pulse generator, usually implanted below the collarbone. The generator sends steady electrical pulses to the electrode tips, and those pulses change the abnormal firing patterns that drive Parkinson symptoms.

The idea rests on a piece of basic neuroscience. Parkinson disease damages the dopamine-producing cells of the substantia nigra, a small structure in the midbrain. Dopamine is the chemical messenger that lets movement circuits run smoothly. When it drops, downstream structures such as the subthalamic nucleus and the globus pallidus, both part of a cluster called the basal ganglia, begin firing in erratic, oversynchronized bursts. Tremor, stiffness and slowness follow.

Stimulating those overactive nodes does not destroy tissue and does not replace dopamine. It acts more like a jamming signal that disrupts the pathological rhythm, which is why many people describe the effect as similar to their best medication response, only smoother and more continuous. Mayo Clinic notes the effect is adjustable and reversible: settings can be changed in clinic, and the system can be switched off.

Three targets are used in Parkinson disease. The subthalamic nucleus is the most common. The globus pallidus interna, a neighboring structure, is often chosen when dyskinesia is the main problem or when there is concern about mood or speech. The ventral intermediate nucleus of the thalamus, a relay station for movement signals, is used mainly for tremor-dominant disease. Which target suits a given person is one of the questions the evaluation answers.

None of this alters the underlying disease. The neurons keep degenerating at their own pace. What changes is how disruptive the symptoms are while that happens, and for how many hours of the day.

Who is a candidate for DBS in Parkinson's? The core checklist clinics use

Across guideline documents and major centers, the profile of a typical candidate is remarkably consistent. Cleveland Clinic, Johns Hopkins and Mayo Clinic describe essentially the same set of conditions, and they are worth reading as a group rather than one at a time, because a person usually needs to meet most of them, not just one.

• A confirmed diagnosis of idiopathic Parkinson disease. Idiopathic simply means the common form with no identified secondary cause. Related conditions that mimic Parkinson disease respond poorly to DBS.
• A clear, ongoing response to levodopa. Levodopa is the medication the brain converts into dopamine. If it still produces a good ‘on’ state, even briefly, that is the single best predictor that stimulation will help.
• Motor complications despite optimized medicine. This means predictable or unpredictable ‘wearing off’ between doses, dyskinesia, or both, interfering with daily life.
• Or tremor that medication no longer controls. Tremor is the one symptom that can respond to DBS even when it barely responds to levodopa.
• No significant dementia. Cognitive decline raises the risk of confusion after surgery and reduces the ability to manage the device.
• Stable mood. Untreated severe depression, active psychosis or unstable anxiety are usually addressed first.
• General health that can tolerate a neurosurgical procedure.
• Realistic expectations, and a support person who can attend programming visits.

Notice what is missing from this list: a specific age, a specific number of years since diagnosis, or a specific severity score. Programs weigh those factors, and later sections explain how, but none is a hard gate on its own. What the evaluation is really testing is whether the symptoms bothering you are the kind DBS reliably changes, and whether the rest of your health leaves room for the procedure to do its work.

Who is not a good candidate for DBS, and who is usually asked to wait

Being told ‘not now’ is more common than being told ‘never,’ and the two carry very different meanings. Clinics separate them deliberately.

People who are generally not considered candidates include those whose symptoms come from an atypical parkinsonian syndrome rather than Parkinson disease itself; those with established dementia; and those whose most disabling problems are symptoms DBS does not treat, such as severe balance loss, freezing that persists even when medication is working, or marked speech and swallowing difficulty. Mayo Clinic and Johns Hopkins both stress that stimulation tends to improve only what levodopa improves. Someone whose walking is unsteady even at their medicated best is unlikely to gain balance from surgery and may find speech worsens.

A second group is asked to wait or prepare. Their disease is real Parkinson disease and their motor symptoms would likely respond, but something else needs attention first. Common reasons include:

• Medication has not yet been fully optimized, and adjustments might restore a workable schedule without surgery.
• Depression or anxiety is active and untreated. Mood disorders are part of Parkinson disease for many people, and stabilizing them first reduces the risk of a difficult recovery.
• Cognitive testing shows mild changes that need repeating over time to see whether they are stable.
• Another medical problem, such as poorly controlled blood pressure, uncontrolled diabetes, or a blood-thinning requirement, needs to be managed before a brain operation is safe.
• The diagnosis is recent enough that the team wants more time to be confident it is idiopathic Parkinson disease.

A third, quieter group are people whose symptoms are still well managed and who are simply exploring options early. Learning what the evaluation involves before it is needed is sensible; the decision itself belongs to a later conversation with the treating team.

Why the evaluation starts by re-checking the diagnosis

It can feel odd, after years of living with a diagnosis, to have a new neurologist question it. Yet this is the first and arguably most consequential step, because the single most common reason DBS disappoints is that the person did not have Parkinson disease in the first place.

Several conditions look like Parkinson disease early on. Multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration are grouped as atypical parkinsonism: they share slowness and stiffness but arise from different patterns of brain damage. NIH describes the key clinical difference plainly: these conditions usually respond poorly or briefly to levodopa and progress faster, often with early falls, early swallowing trouble, prominent eye movement problems, or dramatic blood pressure drops on standing. Because DBS works through the same circuits that levodopa acts on, people with these conditions gain little and may be harmed.

Drug-induced parkinsonism is another mimic, caused by medicines that block dopamine receptors, including some used for nausea or psychiatric conditions. It can improve when the offending medicine is reviewed by the prescriber, which makes surgery unnecessary.

So the movement disorder neurologist repeats the history from the beginning. Did symptoms start on one side of the body? Has levodopa helped clearly and consistently? Have falls come late rather than early? Is there a resting tremor? Were there sleep changes or loss of smell years before diagnosis? Each answer nudges the probability toward or away from idiopathic Parkinson disease.

Brain MRI is ordered or reviewed for two reasons: to rule out structural causes such as stroke, tumor or normal-pressure hydrocephalus, and to provide the detailed anatomy the surgical team will later use for targeting. In selected cases a dopamine transporter scan, a nuclear medicine test that maps dopamine nerve endings, is added to distinguish Parkinson disease from essential tremor or drug-induced symptoms.

Time itself is a diagnostic tool. NIH notes atypical syndromes typically reveal themselves within the first years, which is why many programs prefer a diagnosis that has been established for several years before considering surgery.

The levodopa challenge test for DBS: what it measures and why it matters

If one test defines the DBS evaluation, it is this one. The levodopa challenge, sometimes called the ‘off/on’ assessment, asks a straightforward question: how different are you at your worst and your best?

You arrive in the morning without having taken your usual Parkinson medication, typically since the night before, following instructions the clinic gives in advance. A neurologist or trained nurse examines you in this ‘off’ state using a standardized rating scale, most often the Unified Parkinson’s Disease Rating Scale, which scores tremor, stiffness, finger tapping, hand movements, foot tapping, rising from a chair, gait and posture. Walking is timed. Sometimes it is filmed so the surgical team can review it later.

You then take your usual dose, or a dose the team specifies, and wait. Once the medicine has clearly kicked in, the same examination is repeated. The difference between the two scores is the number everyone is interested in.

Why does this predict surgical benefit? Because stimulation of the subthalamic nucleus or globus pallidus acts on the same circuits dopamine acts on. Mayo Clinic and Cleveland Clinic summarize the principle the same way: symptoms that improve with levodopa are the symptoms most likely to improve with DBS. A large gap between off and on suggests substantial room for stimulation to work. A small gap, meaning you look much the same with or without medication, suggests the disabling symptoms are coming from circuits DBS does not reach, and surgery is unlikely to help.

Each program sets its own threshold for what counts as a meaningful improvement rather than relying on a single universal cutoff, and the score is interpreted alongside everything else the team learns.

Tremor is the exception. Some tremor barely responds to levodopa yet responds well to stimulation, so tremor-dominant patients are not excluded by a modest challenge result.

The test is also useful for you. Seeing the two states side by side, sometimes on video, gives a concrete picture of what a good day might look like more of the time, and what will likely stay the same.

Which Parkinson symptoms DBS helps, and which it usually does not

People often arrive hoping stimulation will address everything at once. It does not, and the evaluation is largely an exercise in matching what troubles you most to what the treatment reliably changes. The pattern below reflects how Mayo Clinic, Johns Hopkins and Cleveland Clinic describe typical responses; individual results vary and the treating team will discuss what applies to you.

Symptom	Typical response to DBS	Why
Tremor	Often improves, even when levodopa helps little	Tremor circuits are directly accessible from all three targets
Rigidity (stiffness)	Often improves	Responds to both levodopa and stimulation
Bradykinesia (slowness)	Often improves to roughly the ‘on’ level	Same dopamine-dependent circuits
Motor fluctuations (wearing off)	Often smoother, with more predictable hours	Continuous stimulation does not wear off between doses
Dyskinesia	Often reduced	Directly with pallidal target; indirectly through lower medication with subthalamic target
Freezing of gait during ‘off’ periods	May improve	Behaves like other levodopa-responsive symptoms
Freezing or imbalance during ‘on’ periods	Usually does not improve; may worsen	Arises from circuits outside the stimulation targets
Speech and swallowing	Usually not improved; speech may soften	Neighboring pathways can be affected by stimulation
Memory and thinking	Not improved; may decline modestly	Cognition is not a motor circuit problem
Mood, apathy, sleep, constipation	Variable or unchanged	Non-motor features driven by wider brain changes

Two lessons follow. First, if your dominant complaint sits in the top half of this table, you are in the territory where stimulation has a track record. Second, if your dominant complaint sits in the bottom half, the team may be candid that surgery would not solve it, and that candor is protective, not discouraging.

A word about the two main targets. The subthalamic nucleus usually allows medication to be reduced afterward, which indirectly eases dyskinesia. The globus pallidus tends to be favored when dyskinesia is severe or when there are concerns about mood or speech. Neither is universally better; the choice is individualized.

Neuropsychological testing: memory, mood and thinking under the microscope

The second pillar of the evaluation happens in a quiet room with a neuropsychologist, a specialist who assesses thinking and behavior through structured tests. The session often runs for a few hours, split across a morning or two visits, and it can feel more demanding than the physical exam.

You will be asked to remember word lists and recall them after a delay, copy figures, name objects, connect numbered dots quickly, generate words beginning with a given letter, and switch between rules mid-task. There are questionnaires about mood, anxiety, impulsive behaviors and hallucinations, sometimes completed separately by a family member. None of it is pass or fail in the school sense. The neuropsychologist is building a profile.

Three concerns drive this part of the assessment. The first is dementia. Parkinson disease affects thinking in many people over time, and Mayo Clinic notes that those with significant cognitive impairment tend to do worse after DBS, with higher rates of postoperative confusion and a risk that thinking declines further. Surgery in the presence of dementia is generally avoided.

The second is mood. Depression is common in Parkinson disease and is treatable. Because stimulation, especially of the subthalamic nucleus, can occasionally affect mood, and because the adjustment period after surgery is emotionally taxing, teams prefer mood to be stable beforehand. A history of suicidal thinking is taken seriously and discussed openly rather than treated as a reason for silence.

The third is executive function, the mental ability to plan, sequence and inhibit impulses. Subtle weakness here can predict difficulties with medication management, device handling and adjusting to a body that suddenly moves differently.

Results are shared with the whole team at a case conference. A borderline profile does not automatically end the conversation; it may prompt a repeat assessment after an interval, a change in target, or extra support planning. The neuropsychologist’s role is to help the team predict how you will experience the transition, not to gatekeep.

Age, other health conditions and the whole-person review

People frequently ask whether they are too old for DBS. The realistic answer is that most programs do not apply a strict upper age limit, but age is a proxy for things that do matter: the state of the heart and lungs, the resilience of thinking, the density of other diagnoses, and the amount of reserve available to recover from a brain operation.

A general medical review therefore sits alongside the neurological one. Blood pressure control matters because the main immediate danger of electrode placement is bleeding into the brain, and high pressure raises that risk. Anticoagulant or antiplatelet medicines, which thin the blood, need a coordinated plan from the prescriber; this is never something to change on your own. Diabetes control affects wound healing and infection risk around the implanted hardware. Heart rhythm problems and lung disease influence how safely anesthesia can be delivered. Cardiac devices such as pacemakers can coexist with DBS but require planning between teams.

Skin and immune health are checked because the pulse generator sits under the skin and the wire runs along the neck; anything that impairs healing raises the chance of infection, which is one of the more common hardware complications listed by Mayo Clinic.

Beyond the body, the team looks at the practical scaffolding of your life. Programming the device takes repeated visits over months, described in a later section. Who will drive you? Who will notice if you seem confused in the first days home? Is there someone who can help track medication changes as doses are adjusted by the neurologist? These questions are not intrusive; they predict whether the benefits of surgery can be realized.

Finally, there is the conversation about expectations. A person who hopes to return to their pre-diagnosis self is set up for disappointment. A person who hopes for more predictable hours, less dyskinesia and a steadier hand is describing what the treatment is designed to do. Part of the whole-person review is simply making sure everyone is imagining the same outcome.

When to consider DBS for Parkinson's: too early, too late, and the window between

Timing is where advice has shifted most over the years, and where reasonable clinicians still differ.

The traditional view held DBS in reserve for advanced disease, after every medication strategy had been exhausted. The drawback of waiting that long is that by the time someone is referred, cognitive changes, balance problems or general frailty may have crept in, closing the window. The NHS and Mayo Clinic frame the current position more moderately: surgery is considered when medication no longer provides adequate, predictable control, not only as a final resort.

Too early has its own risks. In the first years, most people do well on tablets alone, the diagnosis is still being confirmed by the passage of time, and there is no fluctuation for stimulation to smooth out. Operating on a brain that has not yet developed motor complications exposes a person to surgical risk without a clear benefit to offset it. This is why many programs prefer a diagnosis that has been established for several years, a preference tied to the way atypical syndromes declare themselves early, as NIH describes.

The window in the middle is characterized less by a calendar and more by a pattern:

• Doses that once lasted hours now fade sooner, and increasing frequency has become impractical.
• Dyskinesia appears at peak dose and cannot be reduced without bringing back stiffness.
• ‘Off’ periods arrive unpredictably, making planning a day difficult.
• Tremor remains disabling despite a well-designed medication regimen.
• Thinking remains sharp and mood is stable.

A useful signal that a discussion is due: when you and your neurologist find yourselves rearranging the medication schedule every few visits, chasing a balance that never holds. That is the moment many movement disorder specialists suggest a referral for evaluation, even if surgery itself is a year or more away.

Referral is not commitment. A substantial share of people evaluated are advised to continue with medication for now, and re-evaluated later.

What actually happens on surgery day and how the target is chosen

Once the team recommends proceeding, the anatomy of the operation becomes the next set of questions. Knowing the steps tends to make the whole idea less abstract.

Targeting begins with imaging. A high-resolution MRI, sometimes fused with a CT scan taken on the day, lets the surgeon plan a path from a small opening in the skull to the target, avoiding blood vessels. The chosen structure, whether subthalamic nucleus, globus pallidus or thalamus, is only a few millimeters across, so the planning is precise.

Mayo Clinic describes two broad approaches to the procedure. In the traditional awake method, the scalp is numbed and a lightweight frame or platform holds the head still. The person is conscious for part of the operation so the team can record electrical activity from individual neurons through a fine probe and test stimulation in real time, checking that tremor eases and that speech, vision and hand strength remain unaffected. This gives immediate feedback on placement. In the asleep method, the operation is done under general anesthesia and placement is verified by imaging in the operating room. Each approach has advantages; the team’s recommendation depends on anatomy, anxiety, breathing status and their own protocol.

Electrodes are usually placed on both sides of the brain, since Parkinson disease affects both sides, though a single side is sometimes chosen when symptoms are strongly asymmetric. The pulse generator is implanted under the skin of the chest, either the same day or at a second short procedure, and the connecting wire is tunneled under the skin of the neck.

Both awake and asleep approaches carry the same core risks, discussed later: bleeding, infection, stroke and hardware problems. The awake approach adds the challenge of lying still for several hours while ‘off’ medication.

The device is generally not switched on at the end of surgery. Swelling around the electrode can itself dampen symptoms for a while, so programming waits until things settle.

What the following days and weeks usually look like

Recovery from DBS has an unusual shape: a short hospital stay, then a quiet interval, then a long stretch of fine-tuning. People who expect the change to arrive the moment they wake up are often unsettled by this, so it helps to know the pattern in advance.

According to MedlinePlus, the hospital stay after electrode placement is typically measured in a day or two rather than weeks, with longer stays if any complication needs watching. Headache, scalp soreness and fatigue are common. Some people notice temporary improvement in symptoms before the device is even turned on; this is the swelling effect mentioned earlier and it fades.

Mayo Clinic describes activation occurring a few weeks after surgery, once healing is under way. The first programming visit is a systematic exploration: the neurologist tests each contact on each electrode, watching for symptom relief and for side effects such as tingling, pulling sensations in the face or hand, double vision, or slurred speech, which indicate current spreading to neighboring pathways. Settings are chosen that give the most benefit with the fewest unwanted effects, and medications begin to be adjusted downward by the prescribing clinician, never independently.

Over the following months, several more visits refine the settings as the brain adapts and medication changes take hold. Many people reach a stable configuration within a few months; some need longer. During this period, mood swings, irritability and a strange sense of adjusting to a body that behaves differently are common and worth reporting.

Practical restrictions in the early weeks include keeping incisions dry, avoiding heavy lifting or vigorous neck movement, and not driving until cleared. Return to work and usual activities depends on the individual and the team’s advice.

The pulse generator eventually needs replacing. Non-rechargeable units last a number of years depending on settings; rechargeable units last longer but require regular charging. The team can estimate the interval for your specific device once settings are stable.

Risks, side effects and the alternatives that are weighed against surgery

Any evaluation worth its name spends as much time on what could go wrong as on what could go right. The risks of DBS fall into three groups, and Mayo Clinic’s patient information lists each of them.

Surgical risks occur around the operation itself. Bleeding into the brain is the most serious, and it can cause stroke. Infection can develop at the scalp or chest incisions or along the wire, sometimes requiring removal of hardware. Seizures, breathing problems, heart problems and nausea are listed as possible. Confusion in the first days is more common in older people and in those with pre-existing cognitive changes, which is one reason neuropsychological testing carries weight.

Hardware risks arise later: the wire can break or shift, the generator can malfunction, the skin over the device can erode, and batteries need replacement.

Stimulation side effects are the most frequent and the most adjustable: numbness or tingling, muscle tightness in the face or arm, speech that becomes softer or less clear, balance problems, double vision, and changes in mood or behavior. Because these are caused by the current rather than by permanent damage, most can be reduced by reprogramming, though sometimes at the cost of less symptom control.

Against these, the team weighs alternatives. Continued optimization of oral medication, including longer-acting formulations and adjunct drug classes that extend levodopa’s effect, remains the foundation for most people. The NHS describes infusion therapies, in which levodopa or a dopamine agonist is delivered continuously through a small pump under the skin or into the small intestine, as options for those with severe fluctuations who are not suited to, or do not wish to have, brain surgery. Focused ultrasound, which creates a small controlled lesion without an incision, is used for tremor in selected cases but treats one side only and is not adjustable. Exercise, physiotherapy and speech therapy sit alongside every option rather than replacing any.

Which balance is right cannot be decided from an article. It is decided with the treating team, with your priorities on the table.

What people often get wrong about DBS candidacy

Misunderstandings cluster around a handful of ideas, and clearing them up early spares a great deal of worry.

‘DBS is a last resort for the most advanced cases.’ This was the older framing. Waiting until dementia or severe imbalance sets in tends to rule a person out rather than in. The current guideline-level view, reflected by the NHS and Mayo Clinic, is that surgery is considered when medication no longer gives adequate control, while thinking and general health are still good.

‘If it works, I can stop my Parkinson medicine.’ Medication is often reduced, sometimes substantially, particularly with the subthalamic target. Stopping altogether is uncommon, and any change is made gradually by the prescribing neurologist.

‘DBS stops the disease.’ It does not. It treats symptoms. The degeneration continues at its own pace, and non-motor features such as constipation, sleep disturbance and cognitive change progress regardless.

‘Michael J. Fox had DBS, so it must be the standard next step.’ The actor has described publicly that he underwent a thalamotomy, a different procedure in which a small area of the thalamus is deliberately destroyed to reduce tremor on one side, rather than stimulation with an implanted device. His experience is often cited in DBS conversations, but it concerned an older, non-adjustable operation.

‘Most people with Parkinson disease eventually get DBS.’ The reverse is true. It is a treatment for a specific subset with motor complications and preserved cognition. No single figure from the sources cited here defines what share of people ultimately have it, and any percentage you see online should be treated as an estimate, not a benchmark for your own care.

‘Being turned down means the disease is too far gone.’ Often it means the opposite: the disease is not yet causing the complications the treatment addresses, or the diagnosis needs more time. Re-evaluation later is routine.

‘The surgery is the hard part.’ Many people find the months of programming and medication adjustment more demanding than the operation. Knowing this in advance makes it easier to plan.

Questions to ask your care team about who is a candidate for DBS in Parkinson's

The evaluation is a two-way exchange. The team learns about you; you should come away understanding their reasoning. These questions tend to produce the most useful answers.

• What in my history and examination makes you confident this is idiopathic Parkinson disease rather than an atypical syndrome?
• What did my off/on assessment show, and which of my symptoms improved most with medication?
• Which of my symptoms do you expect stimulation to help, and which do you expect it to leave unchanged?
• Which target are you recommending for me, and why that one rather than the alternative?
• What did the neuropsychological testing show, and does anything in it affect your recommendation?
• Are there medication changes we have not yet tried that might delay or avoid surgery?
• What other treatments, such as infusion therapies or focused ultrasound, are relevant to my situation, and how do you see them compared with DBS for me?
• Would you recommend the awake or asleep approach in my case, and what are the trade-offs?
• What are the specific risks for someone with my medical history, and what would you do if a complication occurred?
• How many programming visits should I plan for, and over what period?
• How will my medication be adjusted after surgery, and who will manage that?
• What should my family watch for in the first days at home?
• What is your plan if my thinking or mood changes after the device is switched on?
• If you recommend waiting, what would you want to see change before we revisit the decision?
• What happens if I have the surgery and later decide I do not want stimulation?

Bring a companion who can take notes. Ask for a written summary of the recommendation. If the team’s reasoning does not make sense to you, say so; a good evaluation ends with a shared understanding, not just a verdict.

When to call your doctor

Two situations call for prompt contact with your neurologist or surgical team: problems that arise during the evaluation itself, and warning signs after surgery.

During the evaluation, the levodopa challenge involves going without medication for a period, which can leave some people very stiff, unsteady or anxious. Call the clinic before the appointment if you have had a recent fall, if you feel unsafe being off medication even briefly, or if you have developed new confusion, hallucinations, chest pain or breathlessness. The team can adapt the plan.

After surgery, seek urgent care or call emergency services for:

• Sudden weakness or numbness on one side of the body, facial drooping, difficulty speaking or understanding speech, or sudden severe headache. These can indicate bleeding or stroke.
• A seizure.
• Fever, chills, or redness, warmth, swelling or discharge at any incision, which may signal infection around the hardware.
• Sudden severe confusion, agitation or new hallucinations.
• Chest pain, breathlessness or a rapid, irregular heartbeat.
• A fall with head injury.

Contact the clinic within a day for:

• Sudden return of tremor or stiffness that suggests the device has switched off or a wire has been disturbed.
• New or worsening tingling, muscle pulling, double vision or slurred speech after a programming change.
• Low mood, loss of interest, thoughts of self-harm, or unusual impulsive behavior. Mood changes can follow both stimulation and medication adjustments and are treatable.
• Skin thinning or tenderness over the generator or along the wire.

Never adjust, stop or restart Parkinson medication on your own in response to these signs. The prescribing clinician needs to know what happened and will guide any change. Keep your device identification card with you, and tell any other clinician you see, including dentists and imaging departments, that you have an implanted stimulator, since some equipment requires precautions.

Frequently asked questions

Who qualifies for DBS for Parkinson's?

Someone with confirmed idiopathic Parkinson disease who still responds to levodopa but has troublesome wearing-off, dyskinesia or medication-resistant tremor, with no significant dementia and stable mood. A movement disorder team confirms this through an off/on medication assessment, neuropsychological testing, brain imaging and a general health review before making a recommendation.

Who is not a good candidate for DBS?

People whose symptoms come from an atypical parkinsonian syndrome, those with established dementia, and those whose main problems are balance loss, freezing or speech difficulty that persist even when medication is working. Active untreated depression or psychosis, and medical conditions that make brain surgery unsafe, usually lead to a recommendation to wait and address those first.

What percentage of Parkinson's patients get DBS?

Only a minority, because DBS suits a specific subset with motor complications and preserved cognition. The patient-information sources cited in this article do not publish a single reliable figure, and estimates online vary widely by country and health system, so any percentage should be read as an approximation rather than a guide to whether you personally are a candidate.

Did Michael J. Fox have DBS?

He has described publicly that he underwent a thalamotomy, a procedure in which a small area of the thalamus is deliberately destroyed to reduce tremor on one side, rather than deep brain stimulation with an implanted device. His experience is often mentioned in DBS discussions, but it involved an older, non-adjustable operation.

What does the levodopa challenge test for DBS involve?

You attend without your usual Parkinson medication and are examined and scored on a standardized rating scale in the ‘off’ state, then take your medication and are re-examined once it works. The size of the improvement predicts how much stimulation is likely to help, because DBS acts on the same brain circuits levodopa does.

When should you consider DBS for Parkinson's?

When medication no longer gives adequate, predictable control despite adjustments, typically because doses wear off sooner, dyskinesia appears, or tremor stays disabling, while thinking and general health remain good. Waiting until dementia or severe imbalance develops often closes the window, so many specialists suggest evaluation once the schedule needs frequent rearranging.

Is there an age limit for deep brain stimulation?

Most programs do not apply a strict upper age limit. Age matters as a marker of other factors that do influence the decision: heart and lung health, cognitive reserve, other diagnoses and healing capacity. Older adults with sharp thinking and good general health may be considered, while younger people with dementia may not.

How long does the DBS candidacy evaluation take?

It usually spans several appointments over a number of weeks rather than a single visit, including a neurology consultation, an off/on medication assessment, a neuropsychological session that can last a few hours, brain imaging and a general health review. The team then meets to combine the results before giving a recommendation.

Can you stop Parkinson medication after DBS?

Medication is often reduced after surgery, especially with the subthalamic nucleus target, but stopping completely is uncommon. Any reduction is made gradually by the prescribing neurologist during programming visits, based on how you respond to stimulation. Changing or stopping medication on your own after surgery is not safe.

Does DBS slow down Parkinson disease?

No. Deep brain stimulation treats motor symptoms by altering abnormal electrical activity in movement circuits, but it does not change the underlying loss of dopamine-producing cells. The disease continues to progress, and non-motor symptoms such as cognitive change, sleep problems and constipation develop regardless of stimulation.

References

• NHS: Parkinson's disease: Treatment
• MedlinePlus: Deep brain stimulation
• NIH National Institute of Neurological Disorders and Stroke: Parkinson's Disease
• Cleveland Clinic: Deep Brain Stimulation

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.